Leqembi launch hamstrung by physicians’ ‘therapeutic nihilism’
April 23, 2024
Eisai has recently outlined a range of ways to kick-start Leqembi’s lackluster launch, from increasing the number of neurology account
Eisai has recently outlined a range of ways to kick-start Leqembi’s lackluster launch, from increasing the number of neurology account
Despite a class-wide black box warning for prescribing in the early setting, 31% of providers reported positioning Janus kinase inhibitors
After seven months on the market, Regeneron’s Eylea HD is already making strides with ophthalmologists. According to Spherix Global Insights’
According to Spherix Global Insights, US rheumatologists are most likely to prefer Bimzelx’s dual IL-17A/F pathway as the most efficacious
Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for
Research suggests there will likely be strong uptake for the first USA-approved therapy for metabolic dysfunction-associated steatohepatitis (MASH). Madrigal Pharmaceuticals
Madrigal Pharmaceuticals already has physicians singing from its hymn sheet. Shortly after the biotech won approval in metabolic dysfunction-associated steatohepatitis
In its first few months of U.S. availability, Pfizer’s Velsipity has already made a splash in the moderate to severe
Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the
Excitement grows as the FDA’s first approval for MASH treatment nears commercialization, according to Spherix Global Insights. Exton, PA., April
Takeda’s line extension has outpaced other concurrent launches in adoption and familiarity three months post launch, according to Spherix Global
Research conducted by Spherix Global Insights reveals Retinal Specialists likely to adopt gene therapies. Exton, PA., March 19, 2024 –
